Production (Stage)
Oruka Therapeutics, Inc.
ORKA
$12.58
$0.393.20%
NASDAQ
| 03/31/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -- | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 265.53% | ||||
| Operating Income | -265.53% | ||||
| Income Before Tax | -- | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -- | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -196.72% | ||||
| EBIT | -265.53% | ||||
| EBITDA | -- | ||||
| EPS Basic | 97.39% | ||||
| Normalized Basic EPS | -- | ||||
| EPS Diluted | 97.39% | ||||
| Normalized Diluted EPS | -- | ||||
| Average Basic Shares Outstanding | -- | ||||
| Average Diluted Shares Outstanding | 8,836.45% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||